Advanced Heart Failure and Heart transplantation Unit, Hospital Clinic i Provincial, Barcelona, Spain.
Advanced Heart Failure and Heart transplantation Unit, IDIBELL, L'Hospitalet de Llobregat, Hospital Universitari de Bellvitge, Barcelona, Spain.
Clin Transplant. 2020 Aug;34(8):e13994. doi: 10.1111/ctr.13994. Epub 2020 Jun 28.
Vasoplegic syndrome (VS) is associated with poor outcomes after heart transplantation (HT). Our aim was to determine whether SAC/VALS is associated with VS after HT. We retrospectively analyzed all consecutive HT performed in three centers between January 2017 and August 2018. VS was defined as vasopressor need (norepinephrine or epinephrine >.5 mcg/kg/min or vasopressin) for more than 24 hours to maintain a mean arterial pressure >70 mm Hg. Ninety-six recipients underwent HT in the study period: 60 elective HT with no LVAD, 5 elective HT on long term LVAD, and 31 emergent HT: 3 on long-term LVAD and 28 on temporary mechanical circulatory support. Fourteen patients were on SAC/VALS treatment at the time of transplant, and 82 were not. The global incidence of VS was 15.6%, with no significant differences between the groups (7.14% in with SAC/VALS vs 17.07% in no-SAC/VALS). In conclusion, in our small cohort SAC/VALS was not associated with VS development.
血管麻痹综合征（VS）与心脏移植（HT）后预后不良有关。我们的目的是确定 SAC/VALS 是否与 HT 后的 VS 相关。我们回顾性分析了 2017 年 1 月至 2018 年 8 月在三个中心连续进行的所有 HT。VS 定义为需要血管加压药（去甲肾上腺素或肾上腺素>0.5μg/kg/min 或加压素）超过 24 小时以维持平均动脉压>70mmHg。在研究期间，96 名受者接受了 HT：60 例为非 LVAD 择期 HT，5 例为长期 LVAD 择期 HT，31 例为急诊 HT：3 例为长期 LVAD，28 例为临时机械循环支持。14 名患者在移植时接受 SAC/VALS 治疗，82 名患者未接受 SAC/VALS 治疗。VS 的总体发生率为 15.6%，两组间无显著差异（SAC/VALS 组为 7.14%，无 SAC/VALS 组为 17.07%）。总之，在我们的小队列中，SAC/VALS 与 VS 的发生无关。
